ODELIA - An Open Consortium for Decentralized Medical Artificial Intelligence

人工智能(AI)将给医疗保健带来革命性的变化，因为其诊断性能接近临床专家。特别是，在癌症筛查中，人工智能帮助患者做出更知情的决定，减少医疗错误。然而，这需要大量的数据集，这些数据集的收集面临严重的实践、伦理和法律障碍。这些障碍可以通过群体学习(SL)来克服，在这种学习中，合作伙伴共同训练人工智能模型，而不共享任何数据。然而，获得SL技术的途径受到严重限制，因为没有研究在真正的跨国设置中实施SL，没有实际可用的SL实现，研究人员和医疗保健提供者没有建立SL网络的经验，政策制定者目前没有意识到SL的更广泛影响。Odelia将解决这些问题：Odelia将为SL构建第一个开源软件框架，为简化AI解决方案的开发提供流水线。为了作为未来基于SL的人工智能系统的蓝图，Odelia合作伙伴作为一群人合作，开发了第一个临床上有用的用于在磁共振成像(MRI)中检测乳腺癌的人工智能算法。Odelia的分布式数据库的大小将超过所有以前的研究，Odelia的人工智能模型将在乳腺癌筛查方面达到专家级的性能。因此，Odelia不仅将提供有用的医疗应用，还将证明SL在加速开发、提高性能和强大的普适性方面的临床好处，最终挽救数千名欧洲患者的生命。Odelia的成功将推动合作伙伴成为SL网络指数级增长的核心，并将SL扩展到多种医疗应用。因此，欧洲的患者、医疗保健提供者和公民将获得一个数字基础设施，该基础设施能够在不损害数据安全和数据隐私的情况下开发大数据方面的专家级人工智能工具

ArtifArtificial Intelligence (AI) will revolutionize healthcare as its diagnostic performance approaches that of clinical experts. In particular, in cancerscreening, AI helps patientsto make better-informed decisions and reduce medical error. However, thisrequireslarge datasets whose collection faces severe practical, ethical and legal obstacles. These obstacles can be overcome with swarm learning (SL) where partners jointly train AI models without sharing any data. Yet, access to SL technology is seriously limited because no studies have implemented SL in a true multinational setup, no practically usable implementation of SL is available, researchers & healthcare providers have no experience with setting up SL networks and policymakers are currently unaware of the broader implications of SL. ODELIA will address & solve these issues: ODELIA will build the first open-source software framework for SL, providing an assembly line for the streamlined development of AI solutions. To serve as a blueprint for future SL-based AI systems, ODELIA partners collaborate as a swarm to develop the first clinically useful AI algorithm for the detection of breast cancer in magnetic resonance imaging (MRI). The size of ODELIA's distributed database will exceed all previous studies and ODELIA's AI models will reach expert-level performance for breast cancer screening. Thereby, ODELIA will not only deliver a useful medical application, but prove the clinical benefit of SL in terms of accelerated development, increased performance and robust generalizability to ultimately save thousands of lives of European patients. ODELIA's success will push partners to serve as nuclei for the exponential growth of the SL network and extend SL to a multitude of medical applications. Thus, patients, healthcare providers and citizens in Europe will be provided with a digital infrastructure that enables development of expert-level AI tools on big data without compromising data safety and data privacy